// App-Quantinova.ai

8520 : EFIRM liquid biopsy (eLB) to detect actionable mutations in NSCLC.

Researchers

Presenter

  • David T. Wong

Principal Investigators

  • Fang Wei

  • Wei Liao

  • Ziding Feng

  • David Chia

  • Yong Kim

  • Youlin Qiao

  • Qinghua Zhou

Medical Centers

  • University of California, Los Angeles, Los Angeles, CA

  • University of California, Los Angeles, Los Angeles, CA

  • EZLife BioSciTech Co. Ltd, Guangzhou, China

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Pathology and Laboratory Medicine, Los Angeles, CA

  • University of California, Los Angeles, Los Angeles, CA

  • Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Sichuan Lung Cancer Institute, Chengdu, China

Locations

  • United States

  • China

Companies

  • EZLife BioSciTech Co

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved